Stories
Rossari Biotech Targets 10-15 Percent Growth and Doubling Profits in Four Years
C
CNBC TV18•19-10-2026, 14:47
Rossari Biotech Targets 10-15 Percent Growth and Doubling Profits in Four Years
- •Specialty chemicals company Rossari Biotech retained its annual growth guidance of 10 to 15 percent and aims to double its profits over the next four years.
- •Managing Director Sunil Chari emphasized a strategic focus on improving cash flows, reducing working capital, and enhancing returns on capital and equity.
- •The company reported a revenue of 698 crore rupees and a profit after tax of 39 crore rupees for the July-September quarter.
- •Plans for an expansion facility in Saudi Arabia are underway, though major investments await stabilization of the geopolitical situation in West Asia.
- •Rossari successfully managed raw material price volatility by passing on cost fluctuations to customers, protecting its operating margins.
Key Questions Answered
Rossari Biotech has retained its annual growth guidance of 10-15% for FY27 and expects its profits to double over the next four years.
The company's planned expansion in Saudi Arabia remains part of its long-term growth strategy, but it is currently waiting for the geopolitical situation in West Asia to improve before making major investments.
In the July-September quarter (Q2FY27), Rossari Biotech reported revenue of ₹698 crore, a profit after tax (PAT) of ₹39 crore, and an operating profit margin of 12.50%.
